Gazyva Injection

Introduction

Gazyva Injection 1000 mg/40 ml (also known as Gazyva) is a type of monoclonal antibody given to treat certain types of cancer, including chronic lymphocytic leukemia (CLL). It works by binding to a protein called CD20 which is found on the surface of certain types of B-cells. When bound to CD20, it can cause the B-cells to break down and die.

Uses

Gazyva Injection 1000 mg/40 ml is used to treat advanced and relapsed forms of chronic lymphocytic leukemia (CLL). It is administered with fludarabine and cyclophosphamide in combination, or with bendamustine as monotherapy.

Brand Name	Gazyva
Type	Injection
Weight	1000 mg/40 ml
Generic	Obinutuzumab
Manufacturer	Roche Bangladesh Ltd.
Available in	English বাংলা

Mechanism of Action

Gazyva Injection 1000 mg/40 ml works by binding to a protein called CD20 found on the surface of B-cells, marking them for destruction by the body's immune system. The drug also enhances the activation of other immune cells that help kill cancer cells, including natural killer cells, macrophages, and T-cells.

How Long Does It Take to Work?

Gazyva Injection 1000 mg/40 ml usually takes 7-10 days to start working. The drug works best when it is given on an ongoing basis, so it's important to stick with the treatment plan prescribed by your doctor.

Absorption

Gazyva Injection 1000 mg/40 ml is rapidly absorbed from the subcutaneous tissue after administration and has an elimination half-life of approximately 11 days.

Route of Elimination

Gazyva Injection 1000 mg/40 ml is eliminated by the kidneys. Its metabolites and breakdown products may be eliminated by the liver.

Dosage

Gazyva Injection 1000 mg/40 ml is usually given in a series of 6 weekly injections, or as an infusion over a period of several hours. The dose and duration of therapy will depend on the type of cancer being treated and the patient's overall health.

Administration

Gazyva Injection 1000 mg/40 ml is usually given as a subcutaneous injection, or an IV infusion over a period of several hours. Subcutaneous injections are given into the fatty layer of the skin below the surface of the skin. For IV infusions, the drug is given via a catheter placed into an artery or vein in the arm.

Side Effects

Common side effects of Gazyva Injection 1000 mg/40 ml include flu-like symptoms, urinary tract infections, fatigue, low energy, fever, chills, nausea, headache, diarrhea, injection site reactions, and rash. Serious side effects can include infusion reactions, kidney problems, and an increased risk of infection.

Toxicity

Gazyva Injection 1000 mg/40 ml is generally well-tolerated, but the drug can cause serious side effects. Patients should always discuss possible risks and side effects with their doctor before starting treatment.

Precautions

Patients taking Gazyva Injection 1000 mg/40 ml should receive regular medical check-ups and blood tests to monitor for any possible side effects. Patients should also notify their doctor if they experience any changes in their health or any signs of infection or illness.

Interactions

Gazyva Injection 1000 mg/40 ml may interact with certain medications or supplements, so it is important to inform your doctor of any medications or supplements that you are taking.

Disease Interactions

Gazyva Injection 1000 mg/40 ml may interact with certain diseases or conditions. It should not be used in patients who have had a severe allergic reaction to another similar medication or who have an active infection.

Drug Interactions

Gazyva Injection 1000 mg/40 ml may interfere with the effects of other drugs. It is important to tell your doctor about any other medications you are taking. This includes prescription and over-the-counter medications, as well as vitamins, supplements, and herbal remedies.

Food Interactions

Gazyva Injection 1000 mg/40 ml should not be taken with grapefruit or grapefruit juice, as this may increase the risk of side effects. It is also important to drink plenty of fluids while taking Gazyva Injection 1000 mg/40 ml to prevent dehydration.

Pregnancy and Lactation Use

It is not known if Gazyva Injection 1000 mg/40 ml is safe to use during pregnancy or while breastfeeding. Pregnant women and women who are breastfeeding should discuss the risks and benefits of taking Gazyva Injection 1000 mg/40 ml with their doctor before beginning treatment.

Acute Overdose

If you or someone else experiences an overdose with Gazyva Injection 1000 mg/40 ml, it is important to seek medical attention immediately. Overdose symptoms may include difficulty breathing, dizziness, changes in vision, and nausea.

Contraindication

Gazyva Injection 1000 mg/40 ml should not be used in patients who have had a severe allergic reaction to another similar medication or who have an active infection. Surgery or any other elective procedure should be postponed until after treatment with Gazyva Injection 1000 mg/40 ml is complete.

Use Direction

Gazyva Injection 1000 mg/40 ml should be taken as prescribed by your doctor. It is usually given in a series of 6 weekly injections or as an infusion over a period of several hours. Follow your doctor's instructions for the best results.

Storage Condition

Gazyva Injection 1000 mg/40 ml should be stored in a refrigerator (2°C-8°C) and protected from light. Any unused or expired product should be disposed of properly according to your doctor's instructions.

Volume of Distribution

The volume of distribution for Gazyva Injection 1000 mg/40 ml depends on the dose and route of administration of the drug. The volume of distribution for a subcutaneous dose is approximately 131-178 L, whereas for an IV dose it is approximately 53-106 L.

Half Life

The average half-life of Gazyva Injection 1000 mg/40 ml is approximately 11 days. This means that the drug is slowly eliminated from the body over time.